C3N-02088
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 60.3394935
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.430
- ANGIOGENESIS+0.350
- COAGULATION+0.350
- NOTCH_SIGNALING+0.340
- TGF_BETA_SIGNALING+0.340
- PROTEIN_SECRETION+0.330
- COMPLEMENT+0.250
- KRAS_SIGNALING_UP+0.250
- UV_RESPONSE_DN+0.240
- PEROXISOME+0.220
Top 10 suppressed
- MYC_TARGETS_V2-0.560
- E2F_TARGETS-0.480
- G2M_CHECKPOINT-0.470
- UNFOLDED_PROTEIN_RESPONSE-0.400
- WNT_BETA_CATENIN_SIGNALING-0.320
- MYC_TARGETS_V1-0.290
- APICAL_SURFACE-0.250
- MITOTIC_SPINDLE-0.220
- ALLOGRAFT_REJECTION-0.200
- KRAS_SIGNALING_DN-0.190
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-01021 | — | cohortA1 | 0.807 |
| 2 | SRR8518229 | — | C | 0.782 |
| 3 | C3L-02508 | — | cohortA1 | 0.778 |
| 4 | TCGA-50-5944-01A-11R-1755-07 | — | cohortA1 | 0.755 |
| 5 | 9bc1ce84-45e5-4c83-871c-02356d8311b9 | — | — | 0.740 |
| 6 | TCGA-BH-A0BJ-01A-11R-A056-07 | — | A | 0.739 |
| 7 | SRR8613754 | — | F | 0.737 |
| 8 | TCGA-05-5715-01A-01R-1628-07 | — | cohortA1 | 0.736 |
| 9 | SRR8613790 | — | A | 0.735 |
| 10 | TCGA-44-8120-01A-11R-2241-07 | — | cohortA1 | 0.733 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 21 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.430 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.350 | Remibrutinib | — uncovered |
| COAGULATION | 0.350 | Binimetinib | — uncovered |
| NOTCH_SIGNALING | 0.340 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.340 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.330 | Remibrutinib | — uncovered |
| COMPLEMENT | 0.250 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.240 | Inavolisib | — uncovered |
| PEROXISOME | 0.220 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.190 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.130 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.130 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.110 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.110 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.100 | Idelalisib | — uncovered |
| MYOGENESIS | 0.100 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.090 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.060 | Inavolisib | — uncovered |